---
reference_id: "PMID:27651009"
title: "Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory centers in France."
authors:
- Hommet C
- Novella JL
- Auriacombe S
- Vercelletto M
- Berrut G
- Belliard S
- Desmidt T
- Ceccaldi M
journal: Geriatr Psychol Neuropsychiatr Vieil
year: '2016'
doi: 10.1684/pnv.2016.0629
content_type: abstract_only
---

# Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory centers in France.
**Authors:** Hommet C, Novella JL, Auriacombe S, Vercelletto M, Berrut G, Belliard S, Desmidt T, Ceccaldi M
**Journal:** Geriatr Psychol Neuropsychiatr Vieil (2016)
**DOI:** [10.1684/pnv.2016.0629](https://doi.org/10.1684/pnv.2016.0629)

## Content

1. Geriatr Psychol Neuropsychiatr Vieil. 2016 Sep 1;14(3):274-86. doi: 
10.1684/pnv.2016.0629.

Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory 
centers in France.

[Article in English]

Hommet C(1), Novella JL(2), Auriacombe S(3), Vercelletto M(4), Berrut G(4), 
Belliard S(5), Desmidt T(6), Ceccaldi M(7).

Author information:
(1)CMRR Centre, CHRU Tours et université François Rabelais, Tours, France.
(2)CMRR Champagne Ardenne, CHU Reims, France.
(3)CMRR Aquitaine, CHU Bordeaux, France.
(4)CMRR Pays Loire, CHU Nantes, France.
(5)CMRR Bretagne, CHU Rennes, France.
(6)Service de gérontopsychiatrie, CHRU Tours, France.
(7)CMRR PACA, CHU Marseille, France.

Cholinesterase inhibitors and memantine are used from 15 years, in Alzheimer's 
disease. Benefits have been demonstrated according to cognition, activities of 
daily living, affective symptoms and behavior, and global impression of change. 
The aims of this paper are: 1) to describe how these treatments are used in 
France with a sample survey managed by the national federation of the french 
CMRR; 2) to study data about efficacy, safety, medicoeconomic impacts and how 
they are used in Europe.

DOI: 10.1684/pnv.2016.0629
PMID: 27651009 [Indexed for MEDLINE]